drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (autologous CAR T-cell infusion)
drug_description
Autologous, gene-modified T cells engineered to express a chimeric antigen receptor targeting CD7; antigen engagement triggers T-cell activation, expansion, cytokine release, and cytolytic killing of CD7+ malignant cells, with on-target effects on normal CD7+ T cells and NK cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically modified to express a chimeric antigen receptor targeting CD7. Upon binding CD7 on target cells, CAR signaling activates the T cells, driving expansion, cytokine release, and perforin/granzyme-mediated killing of CD7+ malignant cells, with on-target depletion of normal CD7+ T cells and NK cells.
drug_name
RD13-02 CD7 CAR-T cells
nct_id_drug_ref
NCT05716113